A Retrospective Multicenter Trial on Efficacy and Toxicity of Bendamustine Alone or Associated With Rituximab, as Salvage Therapy in Patients With Chronic Lymphoproliferative Disorders

Gruppo Italiano Studio Linfomi1 site in 1 country109 target enrollmentSeptember 2005

ConditionsRelapsed or Refractory Chronic Lymphoproliferative Disorders

Interventionsbendamustine +/- rituximab

Drugsbendamustine +/- rituximab

Overview

Phase: Not Applicable
Intervention: bendamustine +/- rituximab
Conditions: Relapsed or Refractory Chronic Lymphoproliferative Disorders
Sponsor: Gruppo Italiano Studio Linfomi
Enrollment: 109
Locations: 1
Primary Endpoint: overall response rate
Status: Completed
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This retrospective study collects and evaluates the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative disorders.

Registry

clinicaltrials.gov

Start Date

September 2005

End Date

December 2009

Last Updated

15 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Gruppo Italiano Studio Linfomi

Eligibility Criteria

Inclusion Criteria

•patients with relapsed or refractory chronic lymphoproliferative disorders
•salvage treatment with bendamustine +/- rituximab
•age ≥ 18 years

Exclusion Criteria

•previous treatment with bendamustine

Arms & Interventions

bendamustine +/- rituximab

Intervention: bendamustine +/- rituximab

Outcomes

Primary Outcomes

overall response rate

Time Frame: within 1 month after end of treatment

Secondary Outcomes

prognostic factors(within 1 month after end of treatment)
grade III and IV (NCI Common Toxicity Criteria) adverse events(within 1 month after end of treatment)
progression free survival(within 1 month after end of treatment)
overall survival(within 1 month after end of treatment)